Review on Approved and Inprogress COVID-19 Vaccines

7Citations
Citations of this article
23Readers
Mendeley users who have this article in their library.

Abstract

The last generation of Coronavirus named COVID-19 is responsible for the recent worldwide outbreak. Concerning the widespread and quick predominance, there is a critical requirement for designing appropriate vaccines to surmount this grave problem. Correspondingly, in this revision, COVID-19 vaccines (which are being developed until March 29th, 2021) are classified into specific and non-specific categories. Specific vaccines comprise genetic-based vaccines (mRNA, DNA), vector-based, protein/recombinant protein vaccines, inactivated viruses, live-attenuated vaccines, and novel strategies including microneedle arrays (MNAs), and nanoparticles vaccines. Moreover, specific vaccines such as BCG, MRR, and a few other vaccines are considered Non-specific. What is more, according to the significance of Bioinformatic sciences in the cutting-edge vaccine design and rapid outbreak of COVID-19, herein, Bioinformatic principles including reverse vaccinology, epitopes prediction/selection and, their further applications in the design of vaccines are discussed. Last but not least, safety, challenges, advantages, and future prospects of COVID-19 vaccines are highlighted.

Cite

CITATION STYLE

APA

Farnudian-Habibi, A., Mirjani, M., Montazeri, V., Aliebrahimi, S., Katouzian, I., Abdolhosseini, S., … Rad-Malekshahi, M. (2022, January 1). Review on Approved and Inprogress COVID-19 Vaccines. Iranian Journal of Pharmaceutical Research. Brieflands. https://doi.org/10.5812/ijpr.124228

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free